 | | Vol. 10.15 – 21 April, 2021 |
| |
|
|
| Investigators identified the white matter as a differentiative niche for glioblastomas with oligodendrocyte lineage competency.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists report a regulatory mechanism involving fucosylation by which glucose restriction promoted cancer stemness to drive drug resistance and tumor recurrence.
[Journal of Clinical Investigation] |
|
|
|
| Patient-derived glioma stem cells (GSCs) were established, and MTS, EDU, neurosphere formation, and limiting dilution assays were used to detect the proliferation of GSCs.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Scientists aimed to elucidate the role of bone morphologic protein 9 (BMP9) signaling in hepatocellular carcinoma-cancer stem cells (HCC‐CSC) properties and to assess the therapeutic effect of BMP receptor inhibitors in HCC.
[Molecular Oncology] |
|
|
|
| The authors showed, using DU145 tumor cells, taken as the model of hormone‐refractory and aggressive prostate cancer cells resistant to conventional antineoplastic drugs, that the photoactivated 3 very efficiently eliminated both prostate bulk, differentiated and prostate, hardly treatable cancer stem cells simultaneously and with a similar efficiency.
[Chemistry-A European Journal] |
|
|
|
| Researchers showed significant metabolic alterations occur in gliomas when perturbing the expression of asparagine synthetase, which is not merely restricted to amino acid homeostasis.
[Molecular Cancer Research] |
|
|
|
| Scientists use dCRISPR/Cas9 gene editing with dual gRNAs to introduce large inactivating deletions in the PIM3 gene and achieve stable PIM3 knockout in the human hepatoblastoma cell line, HuH6.
[Cancer Gene Therapy] |
|
|
|
| Investigators used heterogeneous pools of cancer stem cells (CSCs) selected for anoikis resistance from reprogrammed Panc1 and MiaPaCa2 tumor cells (TCs), and adherent TCs reprogrammed from CSCs
[BMC Cancer] |
|
|
|
| Hepatocellular carcinoma tissues and normal controls were collected, and the expression pattern of LINC01013 and miR-6795-5p was identified by quick real-time polymerase chain reaction.
[Acta Biochimica et Biophysica Sinica] |
|  |
|
|
|
| The authors discuss the role of epithelial‐mesenchymal transition of breast CSCs (BCSCs) in the setting of trastuzumab resistance and approaches of reducing or eradicating BCSCs in HER2‐positive breast cancer.
[Stem Cells] |
|
|
|
| Scientists summarize the existing evidence that supports the concept of microvesicles, the tiny particles have a big role behind the rare immortal cancer stem cells which controls the tumor initiation, propagation and metastasis in liver cancer.
[Pharmacological Research] |
|
|
|
| Investigators summarize current evidence-based knowledge on the cancer stem cell niche within the ovarian cancer tumor microenvironment and its effect on immune surveillance.
[International Journal of Molecular Sciences] |
|
|
|
|
| Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced the extension and expansion of their joint Virtual Research and Development Center to explore new molecules from Boehringer Ingelheim’s Kirsten rat sarcoma (KRAS) and TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.
[Boehringer Ingelheim] |
|
|
|
| Incyte and MorphoSys AG announced the first patient has been dosed in the placebo-controlled Phase III inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma.
[Incyte] |
|
|
|
| Vincerx Pharma, Inc. announced that the FDA has cleared the company’s Investigational New Drug Application to initiate a Phase Ib dose-escalation study evaluating VIP152, a highly selective PTEFb/CDK9 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome.
[Vincerx Pharma, Inc.] |
|
|
|
|
| June 21 – 24, 2021
Virtual |
|
|
|
|
|
| | Memorial Sloan Kettering – New York, New York, United States |
|
|
|
| | Dallas, Texas, United States |
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | Karolinska Institutet – Huddinge, Sweden |
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
